Publications by authors named "Isan Chen"

Claim this Profile
F
First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors.
Fernanda I Staquicini, Fenny Hf Tang, Vanessa de Oliveira, Sun-Young Kim, Ethan R Chen, Isan Chen

J Clin Invest· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma.
Robert J Motzer, Thomas E Hutson, Piotr Tomczak, M Dror Michaelson, Ronald M Bukowski, Isan Chen

J Clin Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dysregulation of the PRUNE2/PCA3 genetic axis in human prostate cancer: from experimental discovery to validation in two independent patient cohorts.
Richard C Lauer, Marc Barry, Tracey L Smith, Andrew Maltez Thomas, Jin Wu, Isan Chen

Elife· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study.
Marc Oliva, Douglas Chepeha, Daniel V Araujo, J Javier Diaz-Mejia, Peter Olson, Isan Chen

J Immunother Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
Jeffrey W Clark, D Ross Camidge, Eunice L Kwak, Robert G Maki, Geoffrey I Shapiro, Isan Chen

Future Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A leadership-based program can reduce boarding time of emergency department admissions.
Wan-Ching Lien, Yeh-Ping Liu, I-San Chen, Mei-Luan Huang, Hui-Ning Wang

Am J Emerg Med· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
Guru Sonpavde, Gregory R Pond, Andrew J Armstrong, Matthew D Galsky, Lance Leopold, Isan Chen

BJU Int· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Guru Sonpavde, Gregory R Pond, Andrew J Armstrong, Stephen J Clarke, Janette L Vardy, Isan Chen

Clin Genitourin Cancer· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
M Dror Michaelson, Stephane Oudard, Yen-Chuan Ou, Lisa Sengeløv, Fred Saad, Isan Chen

J Clin Oncol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.
Dana E Rathkopf, Michael J Morris, Josef J Fox, Daniel C Danila, Susan F Slovin, Isan Chen

J Clin Oncol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.
James D Joseph, Nhin Lu, Jing Qian, John Sensintaffar, Gang Shao, Isan Chen

Cancer Discov· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
Xiangao Huang, Maurizio Di Liberto, David Jayabalan, Jun Liang, Scott Ely, Isan Chen, Selina Chen-Kiang

Blood· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
Brian I Rini, Darrel P Cohen, Dongrui R Lu, Isan Chen, Subramanian Hariharan

J Natl Cancer Inst· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
Robert J Motzer, Gary R Hudes, Michelle S Ginsberg, Michael S Baum, Charles S Harmon, Isan Chen

Am J Clin Oncol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
Richard S Finn, Judy Dering, Dylan Conklin, Ondrej Kalous, David J Cohen, Isan Chen

Breast Cancer Res· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
Bernard Escudier, Jan Roigas, Silke Gillessen, Ulrika Harmenberg, Sandhya Srinivas, Isan Chen

J Clin Oncol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
Robert J Motzer, Thomas E Hutson, Piotr Tomczak, M Dror Michaelson, Ronald M Bukowski, Isan Chen

J Clin Oncol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using the Rasch model to validate and enhance the interpretation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index--Disease-Related Symptoms scale.
Xuemei Luo, Joseph C Cappelleri, David Cella, Jim Z Li, Claudie Charbonneau, Isan Chen

Value Health· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa.
David Cella, Joseph C Cappelleri, Andrew Bushmakin, Claudie Charbonneau, Jim Z Li, Isan Chen

J Oncol Pract· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of growing teratoma syndrome.
David J Vaughn, Keith Flaherty, Priti Lal, Maryann Gallagher, Peter O'Dwyer, Isan Chen

N Engl J Med· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Brian I Rini, M Dror Michaelson, Jonathan E Rosenberg, Ronald M Bukowski, Jeffrey A Sosman, Isan Chen

J Clin Oncol· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
David Cella, Jim Z Li, Joseph C Cappelleri, Andrew Bushmakin, Claudie Charbonneau, Isan Chen

J Clin Oncol· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
Eline Menu, Josefina Garcia, Xiangao Huang, Maurizio Di Liberto, Peter L Toogood, Isan Chen, Selina Chen-Kiang

Cancer Res· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Robert J Motzer, Thomas E Hutson, Piotr Tomczak, M Dror Michaelson, Ronald M Bukowski, Isan Chen

N Engl J Med· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases.
Brian I Rini, Vanessa Shaw, Jonathan E Rosenberg, Sindy T Kim, Isan Chen

Clin Genitourin Cancer· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis